1. Home
  2. IRIX vs LEXX Comparison

IRIX vs LEXX Comparison

Compare IRIX & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IRIDEX Corporation

IRIX

IRIDEX Corporation

HOLD

Current Price

$1.17

Market Cap

18.2M

Sector

Health Care

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

N/A

Current Price

$0.57

Market Cap

16.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IRIX
LEXX
Founded
1989
2004
Country
United States
Canada
Employees
N/A
7
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.2M
16.5M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
IRIX
LEXX
Price
$1.17
$0.57
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
56.7K
70.4K
Earning Date
05-12-2026
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
51.85
N/A
EPS
N/A
N/A
Revenue
$41,593,000.00
N/A
Revenue This Year
$3.07
N/A
Revenue Next Year
$6.66
$601.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$0.46
52 Week High
$1.65
$1.55

Technical Indicators

Market Signals
Indicator
IRIX
LEXX
Relative Strength Index (RSI) 56.90 45.12
Support Level $1.01 $0.57
Resistance Level $1.18 $0.70
Average True Range (ATR) 0.04 0.04
MACD -0.00 0.00
Stochastic Oscillator 66.67 28.13

Price Performance

Historical Comparison
IRIX
LEXX

About IRIX IRIDEX Corporation

IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: